ストックスクリーナーアプリを入手
2.24
0.44%
-0.010
アフターアワーズ：
2.23
-0.01
-0.45%
前日終値:
$2.25
開ける：
$2.25
24時間の取引高:
197.41K
Relative Volume:
0.51
時価総額：
$100.84M
収益：
$103.00K
当期純損益:
$-51.85M
株価収益率:
-0.4125
EPS:
-5.43
ネットキャッシュフロー:
$-47.59M
1週間 パフォーマンス:
-5.08%
1か月 パフォーマンス:
-4.68%
6か月 パフォーマンス:
+9.27%
1年 パフォーマンス:
+31.76%
1日の値動き範囲:
$2.18
$2.285
1週間の範囲:
$2.14
$2.39
52週間の値動き範囲:
$1.36
$3.62
Checkpoint Therapeutics Inc Stock (CKPT) Company Profile
名前
Checkpoint Therapeutics Inc
セクター
電話
781-652-4500
住所
95 SAWYER ROAD, WALTHAM, NY
Checkpoint Therapeutics Inc Stock (CKPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-14 | 再開されました | B. Riley Securities | Buy |
| 2021-06-09 | 開始されました | B. Riley Securities | Buy |
| 2021-01-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-05-29 | 開始されました | Lake Street | Buy |
| 2017-12-08 | 開始されました | H.C. Wainwright | Buy |
Checkpoint Therapeutics Inc (CKPT) 最新ニュース
A Closer Look at Checkpoint Therapeutics Inc (CKPT) Stock Gains - The InvestChronicle
Market Resilience: Checkpoint Therapeutics Inc (CKPT) Finishes Weak at 2.22, Down -5.93 - The Dwinnex
Do investors need to be concerned about Checkpoint Therapeutics Inc (CKPT)? - US Post News
Examining the Potential Price Growth of Checkpoint Therapeutics Inc (CKPT) - Knox Daily
Checkpoint Therapeutics Inc (CKPT) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
HC Wainwright Reaffirms Buy Rating for Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
Checkpoint Therapeutics reports promising cosibelimab trial results By Investing.com - Investing.com Canada
Checkpoint Therapeutics reports promising cosibelimab trial results - Investing.com
Checkpoint Therapeutics reports promising cosibelimab trial results - Investing.com India
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 - StockTitan
Checkpoint Therapeutics Announces Cosibelimab Longer-Term - GlobeNewswire
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 - Morningstar
Head to Head Analysis: Checkpoint Therapeutics (NASDAQ:CKPT) & Neoleukin Therapeutics (NASDAQ:NLTX) - Defense World
A company insider recently sold 24,610 shares of Checkpoint Therapeutics Inc [CKPT]. Should You Sale? - Knox Daily
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success - Seeking Alpha
Vanguard Group Inc. Purchases 369,586 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - MarketBeat
EMulate Therapeutics Inc. Announces Publication of Pre-Clinical Mouse Model Demonstrating Direct Evidence of Immune Checkpoint Receptor Knock-Down in a Mouse Glioblastoma Model - Business Wire
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Up 7.4% in July - MarketBeat
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock - Yahoo Finance
Thinking about buying stock in Innoviz Technologies, 22nd Centur - GuruFocus.com
Equities Analysts Issue Forecasts for Checkpoint Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:CKPT) - MarketBeat
Q3 2024 Earnings Estimate for Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Issued By HC Wainwright - Defense World
CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit - Longview News-Journal
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesCKPT - Longview News-Journal
Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Lowered to $20.00 at HC Wainwright - Defense World
CKPT Stock Earnings: Checkpoint Therapeutics Beats EPS, Beats Revenue for Q2 2024 - MSN
Checkpoint Therapeutics (NASDAQ:CKPT) Given New $20.00 Price Target at HC Wainwright - MarketBeat
CKPT Stock Earnings: Checkpoint Therapeutics Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates - ForexTV.com
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates - StockTitan
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Holdings Cut by B. Riley Wealth Advisors Inc. - Defense World
Analysts review Checkpoint Therapeutics Inc’s rating - Knox Daily
Checkpoint Therapeutics Inc (CKPT)’s stock price range in the last year - US Post News
Insider Sale Alert: Checkpoint Therapeutics Inc [CKPT] – Is it Time to sell? - Knox Daily
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm - Kilgore News Herald
Market Resilience: Checkpoint Therapeutics Inc (CKPT) Finishes Weak at 2.42, Down -5.84 - The Dwinnex
CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit - Kilgore News Herald
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class ActionCKPT - Kilgore News Herald
Boehringer inks $1.3B acquisition of Nerio and its preclinical checkpoint inhibitors - Fierce Biotech
CKPT’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab - MarketWatch
Checkpoint Therapeutics Announces FDA Acceptance of BLA - GlobeNewswire
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma - StockTitan
Checkpoint Therapeutics Inc (CKPT) may enjoy gains as insiders got busy in the recent days - Knox Daily
Recent Insider Activity Could Benefit Checkpoint Therapeutics Inc (CKPT) - Knox Daily
Checkpoint Therapeutics’ (CKPT) Buy Rating Reaffirmed at HC Wainwright - Defense World
A closer look at Checkpoint Therapeutics Inc (CKPT)’s stock price trends - US Post News
Checkpoint Therapeutics (NASDAQ:CKPT) Receives Buy Rating from HC Wainwright - MarketBeat
Checkpoint Therapeutics Inc (CKPT) 財務データ
収益
当期純利益
現金流量
EPS
0.05%
4.86%
大文字化:
|
ボリューム (24 時間):